GTP Binding and Oncogenic Mutations May Attenuate Hypervariable Region (HVR)-Catalytic Domain Interactions in Small GTPase K-Ras4B, Exposing the Effector Binding Site*

Background: The HVR is important in K-Ras4B signaling. Results: GTP binding and oncogenic mutations may weaken the HVR-catalytic core interactions. Conclusion: GTP and some oncogenic mutations (e.g. G12C/G12V/Q61H/E37K) could attenuate HVR-catalytic domain interactions at the switch I/effector binding site by direct or longer-range interactions. Significance: GTP and specific mutations could prompt exposure of switch I/effector binding site, thereby up-regulating signaling. K-Ras4B, a frequently mutated oncogene in cancer, plays an essential role in cell growth, differentiation, and survival. Its C-terminal membrane-associated hypervariable region (HVR) is required for full biological activity. In the active GTP-bound state, the HVR interacts with acidic plasma membrane (PM) headgroups, whereas the farnesyl anchors in the membrane; in the inactive GDP-bound state, the HVR may interact with both the PM and the catalytic domain at the effector binding region, obstructing signaling and nucleotide exchange. Here, using molecular dynamics simulations and NMR, we aim to figure out the effects of nucleotides (GTP and GDP) and frequent (G12C, G12D, G12V, G13D, and Q61H) and infrequent (E37K and R164Q) oncogenic mutations on full-length K-Ras4B. The mutations are away from or directly at the HVR switch I/effector binding site. Our results suggest that full-length wild-type GDP-bound K-Ras4B (K-Ras4BWT-GDP) is in an intrinsically autoinhibited state via tight HVR-catalytic domain interactions. The looser association in K-Ras4BWT-GTP may release the HVR. Some of the oncogenic mutations weaken the HVR-catalytic domain association in the K-Ras4B-GDP/-GTP bound states, which may facilitate the HVR disassociation in a nucleotide-independent manner, thereby up-regulating oncogenic Ras signaling. Thus, our results suggest that mutations can exert their effects in more than one way, abolishing GTP hydrolysis and facilitating effector binding.

[1]  G. Superti-Furga,et al.  Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase , 2003, Cell.

[2]  T. Elston,et al.  Divergent Roles of CAAX Motif-signaled Posttranslational Modifications in the Regulation and Subcellular Localization of Ral GTPases* , 2015, The Journal of Biological Chemistry.

[3]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[4]  Xiaolin Nan,et al.  Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway , 2015, Proceedings of the National Academy of Sciences.

[5]  V. Hornak,et al.  Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.

[6]  Ozlem Keskin,et al.  GTP-Dependent K-Ras Dimerization. , 2015, Structure.

[7]  Ruth Nussinov,et al.  The Mechanism of ATP-Dependent Allosteric Protection of Akt Kinase Phosphorylation. , 2015, Structure.

[8]  Ruth Nussinov,et al.  'Pathway drug cocktail': targeting Ras signaling based on structural pathways. , 2013, Trends in molecular medicine.

[9]  C. Ottmann,et al.  The renaissance of Ras. , 2014, ACS chemical biology.

[10]  Kevan M. Shokat,et al.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.

[11]  P. Casey,et al.  The basis for K-Ras4B binding specificity to protein farnesyltransferase revealed by 2 A resolution ternary complex structures. , 2000, Structure.

[12]  E. Castellano,et al.  Functional specificity of ras isoforms: so similar but so different. , 2011, Genes & cancer.

[13]  N. Gebauer,et al.  Applicability of next-generation sequencing to decalcified formalin-fixed and paraffin-embedded chronic myelomonocytic leukaemia samples. , 2014, International journal of clinical and experimental pathology.

[14]  R. Steele,et al.  Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicine , 2010, British Journal of Cancer.

[15]  S. Fesik,et al.  Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.

[16]  I. Mellman,et al.  Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity , 2012, Proceedings of the National Academy of Sciences.

[17]  L. Reymond,et al.  The Efficacy of Raf Kinase Recruitment to the GTPase H-ras Depends on H-ras Membrane Conformer-specific Nanoclustering*♦ , 2014, The Journal of Biological Chemistry.

[18]  Phillip T. Hawkins,et al.  Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ , 2000, Cell.

[19]  Christine Nowak,et al.  Structure of a Ran-binding domain complexed with Ran bound to a GTP analogue: implications for nuclear transport , 1999, Nature.

[20]  J. Hancock,et al.  Ras proteins: different signals from different locations , 2003, Nature Reviews Molecular Cell Biology.

[21]  W. R. Bishop,et al.  Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors Published, JLR Papers in Press, November 8, 2005. , 2006, Journal of Lipid Research.

[22]  J. Mccammon,et al.  H-ras protein in a bilayer: interaction and structure perturbation. , 2007, Journal of the American Chemical Society.

[23]  Hans Robert Kalbitzer,et al.  Metal-bis(2-picolyl)amine complexes as state 1(T) inhibitors of activated Ras protein. , 2012, Angewandte Chemie.

[24]  H. Waldmann,et al.  Membrane binding of lipidated Ras peptides and proteins--the structural point of view. , 2009, Biochimica et biophysica acta.

[25]  V. Gaponenko,et al.  Expression, purification, and characterization of soluble K-Ras4B for structural analysis. , 2010, Protein expression and purification.

[26]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[27]  Ruth Nussinov,et al.  A Unified View of “How Allostery Works” , 2014, PLoS Comput. Biol..

[28]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[29]  Takashi Kumasaka,et al.  Structural Basis for Conformational Dynamics of GTP-bound Ras Protein* , 2010, The Journal of Biological Chemistry.

[30]  Zhi-Xin Wang,et al.  Structural insight into the autoinhibition mechanism of AMP-activated protein kinase , 2009, Nature.

[31]  R. Thapar,et al.  NMR characterization of full-length farnesylated and non-farnesylated H-Ras and its implications for Raf activation. , 2004, Journal of molecular biology.

[32]  T. Schwartz,et al.  Crystallographic and biochemical analysis of the Ran-binding zinc finger domain. , 2009, Journal of molecular biology.

[33]  Ruth Nussinov,et al.  High-Affinity Interaction of the K-Ras4B Hypervariable Region with the Ras Active Site , 2015, Biophysical journal.

[34]  R. Nussinov,et al.  Allosteric effects of the oncogenic RasQ61L mutant on Raf-RBD. , 2015, Structure.

[35]  E K Rowinsky,et al.  Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Grzesiek,et al.  NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.

[37]  J. Meller,et al.  Combined Rational Design and a High Throughput Screening Platform for Identifying Chemical Inhibitors of a Ras-activating Enzyme* , 2015, The Journal of Biological Chemistry.

[38]  P. Poulikakos,et al.  Targeting RAS–ERK signalling in cancer: promises and challenges , 2014, Nature Reviews Drug Discovery.

[39]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[40]  W. Kabsch,et al.  Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical features , 1983, Biopolymers.

[41]  Qi Sun,et al.  Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. , 2012, Angewandte Chemie.

[42]  Alfred Wittinghofer,et al.  GEFs and GAPs: Critical Elements in the Control of Small G Proteins , 2007, Cell.

[43]  F. Calvo,et al.  Ras, an actor on many stages: posttranslational modifications, localization, and site-specified events. , 2011, Genes & cancer.

[44]  Carol L. Williams,et al.  The Chaperone Protein SmgGDS Interacts with Small GTPases Entering the Prenylation Pathway by Recognizing the Last Amino Acid in the CAAX Motif* , 2014, The Journal of Biological Chemistry.

[45]  L. Anderson,et al.  The hypervariable region of K-Ras4B is responsible for its specific interactions with calmodulin. , 2009, Biochemistry.

[46]  Shuai Li,et al.  The Structural Basis of ATP as an Allosteric Modulator , 2014, PLoS Comput. Biol..

[47]  L. Peso,et al.  The Ras family of GTPases in cancer cell invasion , 2000, Cellular and Molecular Life Sciences CMLS.

[48]  R. Nussinov,et al.  Allostery in Disease and in Drug Discovery , 2013, Cell.

[49]  Shaoyong Lu,et al.  Harnessing Allostery: A Novel Approach to Drug Discovery , 2014, Medicinal research reviews.

[50]  B. Brooks,et al.  Self-guided Langevin dynamics simulation method , 2003 .

[51]  Y. Yoshikawa,et al.  Solution Structure of the State 1 Conformer of GTP-bound H-Ras Protein and Distinct Dynamic Properties between the State 1 and State 2 Conformers* , 2011, The Journal of Biological Chemistry.

[52]  Free energy profile of H-ras membrane anchor upon membrane insertion. , 2007, Angewandte Chemie.

[53]  Jacqueline Cherfils,et al.  Regulation of small GTPases by GEFs, GAPs, and GDIs. , 2013, Physiological reviews.

[54]  I R Vetter,et al.  Structural and biochemical analysis of Ras‐effector signaling via RalGDS , 1999, FEBS letters.

[55]  A. Gorfe,et al.  Organization, dynamics, and segregation of Ras nanoclusters in membrane domains , 2012, Proceedings of the National Academy of Sciences.

[56]  B. Brandhuber,et al.  Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition , 2010, PloS one.

[57]  W. R. Bishop,et al.  Lipid posttranslational modifications. Farnesyl transferase inhibitors. , 2006, Journal of lipid research.

[58]  John Kuriyan,et al.  The structural basis of the activation of Ras by Sos , 1998, Nature.

[59]  Carla Mattos,et al.  A comprehensive survey of Ras mutations in cancer. , 2012, Cancer research.

[60]  P. Hawkins,et al.  Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. , 2000, Cell.

[61]  R. Nussinov,et al.  Mechanisms of Membrane Binding of Small GTPase K-Ras4B Farnesylated Hypervariable Region* , 2015, The Journal of Biological Chemistry.